Abstract:Pseudomonas aeruginosa (P. aeruginosa) is a major pathogen that causes infectious diseases. It has high tendency to form biofilms, resulting in the failure of traditional antibiotic therapies. Inspired by the phenomenon that co-culture of Escherichia coli (E. coli) and P. aeruginosa leads to a biofilm reduction, we reveal that E. coli exopolysaccharides (EPS) can disrupt P. aeruginosa biofilm and increase its antibiotic susceptibility. The results show that E. coli EPS effectively inhibit biofilm formation and disrupt mature biofilms in P. aeruginosa, Staphylococcus aureus, and E. coli itself. The maximal inhibition and disruption rates against P. aeruginosa biofilm are 40 % and 47 %, respectively. Based on the biofilm-disrupting ability of E. coli EPS, we develop an E. coli EPS/antibiotic combining strategy for the treatment of P. aeruginosa biofilms. The combination with E. coli EPS increases the antibacterial efficiency of tobramycin against P. aeruginosa biofilms in vitro and in vivo. This study provides a promising strategy for treating biofilm infections. STATEMENT OF SIGNIFICANCE: Biofilm formation is a leading cause of chronic infections. It blocks antibiotics, increases antibiotic-tolerance, and aids in immune evasion, thus representing a great challenge in clinic. This study proposes a promising approach to combat pathogenic Pseudomonas aeruginosa (P. aeruginosa) biofilms by combining Escherichia coli exopolysaccharides with antibiotics. This strategy shows high efficiency in different P. aeruginosa stains, including two laboratory strains, PAO1 and ATCC 10145, as well as a clinically acquired carbapenem-resistant strain. In addition, in vivo experiments have shown that this approach is effective against implanted P. aeruginosa biofilms and can prevent systemic inflammation in mice. This strategy offers new possibilities to address the clinical failure of conventional antibiotic therapies for microbial biofilms.

Biofilms and exopolysaccharides in Pseudomonas aeruginosa : pathogenesis, immune evasion, and lung–brain signaling during pneumonia

Regulation of Biofilm Exopolysaccharide Biosynthesis and Degradation in Pseudomonas aeruginosa

Pathogenesis of the Pseudomonas aeruginosa Biofilm: A Review

The Role of Pseudomonas Aeruginosa Virulence Factors in Cytoskeletal Dysregulation and Lung Barrier Dysfunction

Treatment of Pseudomonas aeruginosa infectious biofilms: Challenges and strategies

The battle within: how Pseudomonas aeruginosa uses host-pathogen interactions to infect the human lung

Mechanisms and Control Strategies of Antibiotic Resistance in Pathological Biofilms

Antimicrobial Resistance and Biofilm Formation of Pseudomonas aeruginosa

Pseudomonas aeruginosa polysaccharide Psl supports airway microbial community development

Ultrasound-Activatable Phase-Shift Nanoparticle As a Targeting Antibacterial Agent for Efficient Eradication Ofpseudomonas Aeruginosabiofilms

Pseudomonas aeruginosa Biofilm Formation and Its Control

P. aeruginosa interactions with other microbes in biofilms during co-infection

Food web and metabolic interactions of the lung inhabitants Streptococcus pneumoniae and Pseudomonas aeruginosa

Intracellular glycosyl hydrolase PslG shapes bacterial cell fate, signaling, and the biofilm development of Pseudomonas aeruginosa

Psl-Dependent Cooperation Contributes to Drug Resistance of Pseudomonas aeruginosa in Dual-Species Biofilms with Acinetobacter baumannii

Escherichia coli exopolysaccharides disrupt Pseudomonas aeruginosa biofilm and increase its antibiotic susceptibility

Unraveling the molecular dynamics of Pseudomonas aeruginosa biofilms at the air–liquid interface

Klebsiella pneumoniae Biofilms and Their Role in Disease Pathogenesis

Pseudomonas aeruginosa behaviour in polymicrobial communities: The competitive and cooperative interactions conducting to the exacerbation of infections

Excellent treatment activity of biscoumarins and dihydropyrans against P. aeruginosa pneumonia and reinforcement learning for designing novel inhibitors

Pseudomonas Aeruginosa Extracellular Products Inhibit Staphylococcal Growth, and Disrupt Established Biofilms Produced by Staphylococcus Epidermidis.